blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2608782

EP2608782 - NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.05.2017
Database last updated on 25.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Algiax Pharmaceuticals GmbH
Max-Planck-Straße 15a
40699 Erkrath / DE
[2013/27]
Inventor(s)01 / KOOPMANS, Guido
Romeinseweg 25
NL-6135 JA Sittard / NL
02 / HASSE, Birgit
Katernberger Str. 171
42115 Wuppertal / DE
03 / MÜLLNER, Stefan
Hagebuttenweg 21
40764 Langenfeld / DE
 [2013/27]
Representative(s)Roth, Andy Stefan
Dr. Roth Patentanwaltskanzlei
Kaistrasse 5
40221 Düsseldorf / DE
[N/P]
Former [2013/27]Roth, Andy Stefan
Dr. Roth Patentanwaltskanzlei
Life Science
Columbusstrasse 22
40549 Düsseldorf / DE
Application number, filing date11754832.123.08.2011
[2016/26]
WO2011EP04218
Priority number, dateEP2010000880224.08.2010         Original published format: EP 10008802
US20100376453P24.08.2010         Original published format: US 376453 P
[2013/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012025217
Date:01.03.2012
Language:EN
[2012/09]
Type: A1 Application with search report 
No.:EP2608782
Date:03.07.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.03.2012 takes the place of the publication of the European patent application.
[2013/27]
Type: B1 Patent specification 
No.:EP2608782
Date:29.06.2016
Language:EN
[2016/26]
Search report(s)International search report - published on:EP01.03.2012
ClassificationIPC:A61K31/165, A61K31/42, A61P25/00
[2013/27]
CPC:
A61K31/42 (EP,US); A61K31/167 (EP,US); A61K31/277 (EP,US);
A61P17/02 (EP); A61P25/00 (EP); A61P9/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUE ANWENDUNGEN VON LEFLUNOMID UND MALONONITRILAMIDEN[2016/08]
English:NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES[2013/27]
French:NOUVELLES UTILISATIONS DE LEFLUNOMIDE ET MALONONITRILAMIDES[2016/08]
Former [2013/27]NEUARTIGE VERWENDUNG VON LEFLUNOMID UND MALONONITRILAMIDEN
Former [2013/27]NOUVELLE UTILISATION DE LÉFLUNOMIDE ET DE MALONONITRILAMIDES
Entry into regional phase11.03.2013National basic fee paid 
11.03.2013Designation fee(s) paid 
11.03.2013Examination fee paid 
Examination procedure11.03.2013Examination requested  [2013/27]
09.10.2013Amendment by applicant (claims and/or description)
23.01.2014Despatch of a communication from the examining division (Time limit: M04)
27.05.2014Reply to a communication from the examining division
17.06.2014Despatch of a communication from the examining division (Time limit: M02)
24.06.2014Reply to a communication from the examining division
15.09.2015Despatch of a communication from the examining division (Time limit: M02)
13.10.2015Reply to a communication from the examining division
01.02.2016Communication of intention to grant the patent
20.05.2016Fee for grant paid
20.05.2016Fee for publishing/printing paid
20.05.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.01.2014
Opposition(s)30.03.2017No opposition filed within time limit [2017/23]
Fees paidRenewal fee
29.08.2013Renewal fee patent year 03
28.08.2014Renewal fee patent year 04
27.08.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.08.2011
AL29.06.2016
BE29.06.2016
CY29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
MK29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
TR29.06.2016
IE23.08.2016
LU23.08.2016
MT31.08.2016
BG29.09.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
[2018/46]
Former [2018/31]HU23.08.2011
BE29.06.2016
CY29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
MK29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
TR29.06.2016
IE23.08.2016
LU23.08.2016
MT31.08.2016
BG29.09.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2018/29]HU23.08.2011
BE29.06.2016
CY29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
MK29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
TR29.06.2016
IE23.08.2016
LU23.08.2016
BG29.09.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2018/28]HU23.08.2011
BE29.06.2016
CY29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
MK29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
IE23.08.2016
LU23.08.2016
BG29.09.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/41]BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SI29.06.2016
SK29.06.2016
SM29.06.2016
IE23.08.2016
LU23.08.2016
BG29.09.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/23]BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
MC29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SK29.06.2016
SM29.06.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/11]BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SK29.06.2016
SM29.06.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
PT31.10.2016
Former [2017/10]BE29.06.2016
CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
PL29.06.2016
RO29.06.2016
RS29.06.2016
SK29.06.2016
NO29.09.2016
GR30.09.2016
IS29.10.2016
Former [2017/09]CZ29.06.2016
EE29.06.2016
FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RO29.06.2016
RS29.06.2016
BE31.08.2016
NO29.09.2016
GR30.09.2016
Former [2017/03]FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RS29.06.2016
BE31.08.2016
NO29.09.2016
GR30.09.2016
Former [2016/51]FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RS29.06.2016
NO29.09.2016
GR30.09.2016
Former [2016/50]FI29.06.2016
HR29.06.2016
LT29.06.2016
LV29.06.2016
RS29.06.2016
NO29.09.2016
Former [2016/49]FI29.06.2016
LT29.06.2016
NO29.09.2016
Former [2016/46]LT29.06.2016
NO29.09.2016
Cited inInternational search[XI]US2003223960  (WETTSTEIN JOSEPH [US]) [X] 2,12,13,15,16 * claims 1-32 * * figure 1 * [I] 3,7;
 [XP]EP2314291  (SANOFI AVENTIS [FR]) [XP] 2,11-13,15,16 * the whole document *;
 [XI]US5556870  (WEITHMANN KLAUS U [DE], et al) [X] 1-3,11-13,15,16 * claim 1 * [I] 7;
 [XI]WO2009133141  (PHARNEXT [FR], et al) [X] 1-3,11-13,15,16 * the whole document * [I] 7;
 [XI]WO0050079  (TOBINICK EDWARD L [US], et al) [X] 1-3,8-13,15,16,18-20 * page 5, paragraph 2 * * claims 27,32,34,25,47 * [I] 7;
 [I]EP0821952  (HOECHST AG [DE]) [I] 4,5,7,14,17 * claim 4 *;
 [XI]  - SCHORLEMMER H U ET AL, "Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental, allergic encephalomyelitis (EAE)", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, (1997), vol. 23, no. 5-6, ISSN 0378-6501, pages 175 - 181, XP009153516 [X] 3-5,11-17 * the whole document * [I] 7
 [XI]  - PETTY MARGARET ET AL, "Teriflunomide Treatment Reduces Infiltration of Macrophages, T Cells and B Cells, and Increases Survival of Oligodendrocytes in the Spinal Cord of the Dark Agouti Rat Model of Experimental Allergic Encephalomyelitis", NEUROLOGY, & 62ND ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; TORONTO, CANADA; APRIL 10 -17, 2010, (201003), vol. 74, no. 9, Suppl. 2, ISSN 0028-3878, page A415, XP009153517 [X] 2,8,11-13,15,16,18,19 * the whole document * [I] 7
 [XI]  - BELEN D ET AL, "Leflunomide prevents vasospasm secondary to subarachnoid haemorrhage", ACTA NEUROCHIRURGICA ; THE EUROPEAN JOURNAL OF NEUROSURGERY, SPRINGER-VERLAG, VI, (20070917), vol. 149, no. 10, doi:10.1007/S00701-007-1275-1, ISSN 0942-0940, pages 1041 - 1048, XP019565304 [X] 1-3,11-13,15,16 * the whole document * [I] 7

DOI:   http://dx.doi.org/10.1007/s00701-007-1275-1
 [I]  - COHEN JEAN-DAVID ET AL, "Leflunomide-induced aseptic meningitis.", JOINT, BONE, SPINE : REVUE DU RHUMATISME MAY 2004 LNKD- PUBMED:15182800, (200405), vol. 71, no. 3, ISSN 1297-319X, pages 243 - 245, XP002662326 [I] 1-3,7,11-13,15,16 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1297-319X(03)00127-1
by applicantUS5532259
 WO9117748
 WO2004006834
 US3845770
 US3916899
 US3536809
 US3598123
 US4008719
 US5674533
 US5059595
 US5591767
 US5120548
 US5073543
 US5639476
 US5354556
 US5733566
 US5134127
    - Burger's Medicinal Chemistry and Drug Discovery, (1995), vol. 172-178, pages 949 - 982
    - WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
    - WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - Oxford Dictionary of Biochemistry and Molecular Biology, OXFORD UNIVERSITY PRESS
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 80
    - BASSO, D. M. ET AL., "A sensitive and reliable locomotor rating scale for open field testing in rats", J NEUROTRAUMA., (1995), vol. 12, pages 1 - 21, XP009036806
    - DAVIS, J. P ET AL., "The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase", BIOCHEMISTRY, (1996), vol. 35, pages 1270 - 3
    - GREENE, S. ET AL., "Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide", BIOCHEM PHARMACOL., (1995), vol. 50, doi:doi:10.1016/0006-2952(95)00255-X, pages 861 - 7, XP002074075

DOI:   http://dx.doi.org/10.1016/0006-2952(95)00255-X
    - HIMES, B. T. ET AL., "Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord", NEUROREHABIL NEURAL REPAIR., (2006), vol. 20, pages 278 - 96
    - KUO, E. A. ET AL., "Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds", J MED CHEM., (1996), vol. 39, doi:doi:10.1021/jm9604437, pages 4608 - 21, XP000196780

DOI:   http://dx.doi.org/10.1021/jm9604437
    - SHUMSKY, J. S. ET AL., "Delayed transplantation of fibroblasts genetically modified to secrete BDNF and NT-3 into a spinal cord injury site is associated with limited recovery of function", EXP NEUROL., (2003), vol. 184, pages 114 - 30
    - WILLIAMSON, R. A. ET AL., "Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound", J BIOL CHEM., (1995), vol. 270, pages 22467 - 72
    - ZIELINSKI, T. ET AL., "Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?", INFLAMM RES., (1995), vol. 44, no. 2, doi:doi:10.1007/BF01782026, pages 207 - 8, XP002061643

DOI:   http://dx.doi.org/10.1007/BF01782026
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.